MBC-11
Product Specifications
UNSPSC Description
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MBC-11.html
Solubility
10 mM in DMSO
Smiles
CC(P(O)(O)=O)(P(O)(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)=O)O
Molecular Weight
511.21
References & Citations
[1]Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22.|[2]Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24(3):303-e102.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-107093/MBC-11-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-107093/
Clinical Information
Phase 1
CAS Number
332863-86-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1155406-01 1 mg (E-Coli)
Recombinant Prochlorococcus marinus NAD (P)H-quinone oxidoreductase chain 4, partial
Ask
View Details 
MBS1155406-02 1 mg (Yeast)
Recombinant Prochlorococcus marinus NAD (P)H-quinone oxidoreductase chain 4, partial
Ask
View Details 